Mazdutide ~
Mazdutide 5mg $79.99 - 10% off / code: GLAMFIT
Introduction.
If you have been following my weight-loss content, then you probably already know that GLP-1 medications and peptides have become a pretty big part of my life over the last six months. Not because I woke up one morning and decided I wanted to become a walking encyclopedia of metabolic hormones, although apparently that is where we're at now, but because I am currently going through my own weight-loss journey.
I started this journey at 287 pounds. Yep. Two hundred and eighty-seven pounds. I was knocking on 300's door, and thankfully I decided I didn't want anyone answering.
At 5'7" and 38 years old, I knew something needed to change. What makes my story a little different is that I wasn't overweight my entire life. For most of my life, I was naturally thin and pretty fit. It wasn't until roughly the last 10 years, after dealing with health issues and medications that contributed to weight gain, that my weight really started climbing.
Over the past six months of using a GLP-1 along with researching and using different peptides, I've lost 70 pounds.
That puts me at around 217 pounds today.
My first major goal is 200 pounds, which means I only have 17 pounds to go before hitting that milestone. Ultimately, I'd still like to lose another 45–55 pounds, so I'm definitely not at the finish line yet. But when I look at where I started compared with where I am now, I'm incredibly excited about my progress.
So why am I suddenly researching Mazdutide for weight loss?
Because I like having options.
One thing I've learned during this journey is that obesity treatment isn't necessarily a straight line. A medication that works incredibly well for someone today may not always be the medication they use forever. Response, tolerability, health needs and available treatments can all change.
That's why I've been doing a ton of research into Mazdutide, also known as IBI362 or LY3305677.
I'm not currently writing this as a Mazdutide review or pretending that I've personally used it. I haven't. This article is informational and based on the clinical research available so far.
I'm researching Mazdutide because I want to understand what other options are being developed in the GLP-1 world. If I ever reach a point where my current treatment isn't the right fit anymore, I want to already understand the alternatives I could discuss with a medical professional.
And Mazdutide is especially interesting because technically it isn't just another GLP-1.
It's a dual GLP-1 and glucagon receptor agonist, and that second pathway could make a pretty important difference for some people.
This guide is for anyone researching:
• Mazdutide for weight loss.
• Mazdutide results.
• Mazdutide vs Tirzepatide.
• Mazdutide vs Retatrutide.
• Mazdutide vs Semaglutide.
• GLP-1 and glucagon medications.
• New weight-loss medications.
• Next-generation GLP-1 drugs.
• Mazdutide clinical trials.
• Mazdutide side effects.
• Mazdutide dosing studied in clinical trials.
If you've been staring at all these names thinking, Didn't we just learn how to pronounce Tirzepatide?, don't worry. I'm right there with you.
Let's get into it.
What Is a GLP-1 Drug?
Get 10% off all of your research materials with code - GLAMFIT
Before getting specifically into Mazdutide, it helps to understand what people mean when they talk about a GLP-1 medication.
GLP-1 stands for glucagon-like peptide-1. It's a hormone that our bodies naturally release, particularly after eating. Among other things, GLP-1 helps regulate blood sugar, insulin secretion, digestion, appetite and feelings of fullness.
GLP-1 receptor agonist medications basically imitate some of those natural GLP-1 signals.
One of the reasons these medications can be so helpful for weight management is that they don't simply depend on someone waking up every morning with superhero-level willpower.
GLP-1 signaling can influence the brain's appetite centers and slow gastric emptying, which can help people feel satisfied with less food. In people with type 2 diabetes, GLP-1 receptor activation can also stimulate glucose-dependent insulin secretion and improve blood-sugar control.
That's why medications in this general family have completely changed the conversation around obesity.
They aren't all identical, either.
Semaglutide primarily targets GLP-1 receptors.
Tirzepatide targets GLP-1 and GIP receptors.
Mazdutide targets GLP-1 and glucagon receptors.
And Retatrutide targets GLP-1, GIP and glucagon receptors.
Apparently metabolic medications are collecting receptors like Pokémon now.
For appropriate patients, GLP-1-based medications may be considered when overweight or obesity is affecting health and lifestyle changes alone haven't produced enough improvement. They're also widely used in type 2 diabetes, depending on the particular medication and its approved indications.
They aren't appropriate for everybody, though. Medical history, other medications, pregnancy, gastrointestinal conditions and other health factors can affect whether a particular treatment makes sense.
What Is Mazdutide?
Get 10% off all of your research materials with code - GLAMFIT
Mazdutide is a long-acting dual GLP-1 receptor and glucagon receptor agonist.
You may also see it called:
• Mazdutide.
• IBI362.
• LY3305677.
• OXM3.
Mazdutide is related to the natural hormone oxyntomodulin, or OXM. It was designed to activate two different metabolic receptors at the same time, the GLP-1 receptor and the glucagon receptor.
That combination is what immediately caught my attention.
Traditional GLP-1 receptor agonists primarily lean on the GLP-1 pathway. Mazdutide adds glucagon receptor activation to the equation.
In very simplified terms, the goal is to potentially attack obesity from two directions, eat less + influence energy metabolism.
The GLP-1 side contributes to appetite regulation, satiety and glucose control, while glucagon receptor activation may increase energy expenditure and affect hepatic fat metabolism.
Mazdutide originated from Eli Lilly's metabolic-drug research, and Innovent Biologics obtained rights to develop and commercialize it in China. It is a long-acting synthetic oxyntomodulin analogue engineered for once-weekly administration.
And this is no longer simply an early-stage experimental molecule.
Mazdutide became the first approved dual GLP-1/glucagon receptor agonist when China's National Medical Products Administration approved it for chronic weight management in June 2025. China subsequently approved Mazdutide for glycemic control in adults with type 2 diabetes in September 2025.
That distinction matters.
As of 2026, however, Mazdutide is not FDA-approved in the United States.
So when people in the U.S. discuss Mazdutide right now, its Chinese approval and clinical-trial evidence need to be separated from its U.S. regulatory status.
How Mazdutide Works.
Get 10% off all of your research materials with code - GLAMFIT
This is probably my favorite part of researching Mazdutide because its mechanism is what makes it different from several medications we're already familiar with.
Mazdutide activates two receptors simultaneously:
GLP-1 Receptor Activation.
GLP-1 receptor activation can:
• Increase glucose-dependent insulin secretion.
• Help regulate blood glucose.
• Reduce appetite.
• Increase feelings of fullness.
• Slow gastric emptying.
• Reduce overall calorie intake.
Basically, this is the side of Mazdutide that will sound familiar if you've already spent time researching Semaglutide or other GLP-1 medications.
For someone like me who is actively trying to lose a substantial amount of weight, appetite regulation is obviously a huge piece of the puzzle.
But Mazdutide has another trick up its tiny pharmaceutical sleeve.
Glucagon Receptor Activation.
Glucagon is often talked about as insulin's opposite because it can raise blood glucose under certain conditions. That can make the idea of intentionally activating glucagon receptors sound strange at first.
But metabolism is way more complicated than "insulin good, glucagon bad."
Glucagon signaling also affects energy expenditure and liver metabolism.
Mazdutide's glucagon component is being studied for its ability to increase energy expenditure and improve hepatic fat metabolism. Glucagon receptor activation may encourage fat oxidation and alter how the liver processes and stores fat.
This could help explain why Mazdutide trials have shown particularly interesting changes in waist circumference and liver fat.
Why Combine GLP-1 + Glucagon?
This is where the entire concept starts making sense.
GLP-1 helps reduce incoming energy by influencing appetite and food intake.
Glucagon signaling may influence the other side of the equation by increasing energy expenditure and affecting fat metabolism.
So instead of only asking: "How do we make someone less hungry?"
Researchers are also asking: "Can we change how the body handles and expends energy?"
That dual approach is one of the biggest reasons Mazdutide has landed on my personal GLP-1 research radar.
Clinical Benefits and Real-World Experiences.
Get 10% off all of your research materials with code - GLAMFIT
Mazdutide has moved beyond the stage where we're looking at a tiny preliminary trial and crossing our fingers.
We now have substantial Phase 3 data.
Mazdutide Weight-Loss Results: GLORY-1.
The Phase 3 GLORY-1 trial included 610 Chinese adults with overweight or obesity.
At 32 weeks, average body-weight changes were approximately:
• -10.1% with Mazdutide 4 mg.
• -12.6% with Mazdutide 6 mg.
• +0.45% with placebo.
By week 48, average reductions reached approximately:
• 11.0% with 4 mg.
• 14.0% with 6 mg.
Nearly half of participants receiving 6 mg achieved at least 15% weight loss by week 48.
That's definitely enough to make me raise an eyebrow in a good way.
The study also found improvements across prespecified cardiometabolic measurements.
Waist Circumference and Liver Fat.
Scale weight isn't everything.
One of the things I find particularly interesting about Mazdutide is what happened to waist circumference and liver fat.
Using the efficacy analysis reported by Innovent, average waist-circumference reductions at week 48 were approximately 9.5 cm with 4 mg and 11 cm with 6 mg.
Among participants who began with liver fat content of at least 10%, liver fat decreased by approximately 66% with 4 mg and 80% with 6 mg.
Those are seriously interesting numbers.
GLORY-2: The Higher-Dose 9 mg Results.
Then things got even more interesting.
The Phase 3 GLORY-2 trial evaluated 9 mg Mazdutide in adults with obesity.
At week 60, participants receiving Mazdutide had lost an average of approximately 18.6% of their starting body weight, compared with about 3% with placebo.
Among participants without type 2 diabetes, average weight loss reached approximately 20.1%.
Nearly half of the participants without diabetes achieved at least 20% weight loss.
Even more interesting, weight loss had not clearly plateaued at week 60.
Twenty percent is a big deal.
For perspective, someone starting at 250 pounds would be looking at roughly 50 pounds if they experienced a 20% reduction.
Obviously clinical-trial averages don't predict what one individual will lose. Some participants lose considerably more, some less and some may discontinue treatment.
But those results put Mazdutide firmly into the conversation about next-generation obesity medications.
Blood Sugar and Metabolic Benefits.
Weight loss isn't the only story.
Clinical studies have also reported improvements in:
• HbA1c.
• Fasting glucose.
• Insulin sensitivity.
• Waist circumference.
• Blood pressure.
• Triglycerides and other lipids.
• Serum uric acid.
• Liver enzymes.
• Liver fat.
The 2026 DREAMS-3 trial is especially interesting because researchers compared Mazdutide 6 mg directly with Semaglutide 1 mg in Chinese adults who had type 2 diabetes and obesity.
At week 32, average weight reduction was 10.3% with Mazdutide versus 6.0% with Semaglutide. HbA1c decreased by 2.03 percentage points with Mazdutide versus 1.84 with Semaglutide.
Nearly 48% of Mazdutide participants simultaneously reached an HbA1c below 7% and lost at least 10% of their body weight, compared with 21% receiving Semaglutide.
One important caveat, that trial used Semaglutide 1 mg in people with diabetes, so I wouldn't take those numbers and claim Mazdutide has definitively beaten every Semaglutide obesity regimen. That's not what the study tested.
What About Real-World Mazdutide Experiences?
Get 10% off all of your research materials with code - GLAMFIT
Mazdutide has only been commercially available in China since 2025. That means its real-world evidence is nowhere near as mature as something like Semaglutide.
There are obviously experiences being shared online, but anecdotes aren't clinical trials.
Someone saying, "I lost 20 pounds!" doesn't tell us their starting weight, diet, dose, medical history, side effects, other medications or whether the product they used was even authentic pharmaceutical Mazdutide.
BUT, with that being said, the real world evidence that I've read about has been so promising. Yes it's not actual clinical evidence but enough real life experiences eventually carries weight. Not only am I reading that people are quieting their food noise and losing weight, they are also talking about a boost in energy and endurance too. All of this has me adding Mazdutide to my list of weight-loss medication replacement options.
Mazdutide vs Other Weight-Loss Drugs.
Get 10% off all of your research materials with code - GLAMFIT
Here's where things get fun.
The newer generation of obesity medications isn't simply producing different versions of the same GLP-1 drug.
Researchers are combining metabolic pathways in different ways.
Mazdutide.
Targets: GLP-1 + glucagon.
Mazdutide combines appetite and glucose effects associated with GLP-1 activation with glucagon receptor activation that may increase energy expenditure and influence liver-fat metabolism.
Not only am I reading that people are quieting their food noise and losing weight, they are also talking about a boost in energy and endurance too. For myself, I haven't tried it yet.
Tirzepatide.
Targets: GLP-1 + GIP.
Tirzepatide uses an entirely different second receptor.
Rather than glucagon, it activates GIP, or glucose-dependent insulinotropic polypeptide receptors.
Tirzepatide is already FDA-approved in the United States as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and certain additional indications.
For myself, Tirzepatide has been one of my favorites. It's actually the main weight-loss drug that I'm using. It's the best at quieting food noise. I've tried many of the approved and non-approved weight-loss medications but I always fall back on Tirzepatide.
Retatrutide.
Targets: GLP-1 + GIP + glucagon.
Retatrutide essentially brings all three pathways together.
That's why you'll hear it called a triple agonist.
Its Phase 2 obesity trial generated huge excitement after participants receiving the highest studied dose lost an average of roughly 24% of their body weight after 48 weeks.
For myself, Retatrutide wasn't my favorite. I even mixed it with Tirzepatide and then with Cagrilintide but it didn't give me the right amount of food noise suppression. Retatrutide also makes me super sleepy.
Retatrutide remains investigational as of this writing BUT it can be obtained through peptide companies for research purposes.
Semaglutide.
Targets: GLP-1.
Semaglutide doesn't use GIP or glucagon receptor agonism.
Yet it has become one of the medications responsible for bringing GLP-1 treatment into mainstream conversation.
For myself, Semaglutide was absolutely terrible. I immediately had bad side-effects. I was nauseous all the time with bad stomach cramps. The worst part was I was in and out of the hospital for chronic kidney infections and kidney stones too. Once I quit taking Semaglutide, that all stopped.
So Which One Is Best?
I don't think we can responsibly declare one universal winner.
And I definitely don't think weight-loss percentages alone tell the entire story.
The "best" medication is ultimately the one that provides meaningful benefits that a particular patient can safely tolerate and sustain under appropriate medical care.
Mazdutide's biggest differentiator is the glucagon pathway without GIP.
Tirzepatide combines GLP-1 with GIP.
Retatrutide combines all three.
That gives researchers three fascinating approaches to the same enormous problem.
And as someone who still wants to lose another 45–55 pounds myself, I love knowing that obesity medicine isn't standing still.
Development Status, Safety and Future Outlook.
Get 10% off all of your research materials with code - GLAMFIT
Mazdutide's regulatory status can get confusing because you'll see websites simultaneously describing it as "approved" and "investigational."
Both can technically be true depending on the country.
Current Mazdutide Status.
China: Approved for chronic weight management in adults with overweight or obesity in June 2025.
China: Approved for glycemic control in adults with type 2 diabetes in September 2025.
United States: Not FDA-approved as of this article but can be obtained through peptide companies for research purposes.
A higher 9 mg Mazdutide regimen has separately been studied for moderate-to-severe obesity, with a Chinese regulatory application submitted following the GLORY-2 program.
Mazdutide Side Effects.
Like other medications involving GLP-1 signaling, gastrointestinal symptoms have been common.
These can include:
• Nausea.
• Vomiting.
• Diarrhea.
• Reduced appetite.
• Other digestive symptoms.
GLORY-1 reported that the most common adverse events were gastrointestinal and generally mild to moderate.
Interestingly, discontinuation because of adverse events was relatively low in that study, 1.5% with 4 mg and 0.5% with 6 mg.
But I wouldn't describe Mazdutide as practically side-effect-free.
That becomes especially clear when looking at the higher 9 mg GLORY-2 trial.
Vomiting was reported in about 53%, nausea in 47% and diarrhea in 39% of Mazdutide participants. About 2.9% discontinued treatment because of adverse events.
Injection-site reactions and sinus tachycardia were also reported more frequently with Mazdutide than placebo.
So yes, promising?
Absolutely.
Magic skinny shot with zero downsides?
Nope. That unicorn remains missing.
Why Long-Term Research Still Matters.
Mazdutide is new.
That means we don't yet have the same depth of long-term, worldwide real-world experience that exists for older medications.
Researchers are also studying Mazdutide across additional metabolic conditions, including obesity associated with fatty-liver disease and obstructive sleep apnea.
I'm particularly interested in what future studies tell us about cardiovascular outcomes, long-term maintenance, body composition and whether its liver-fat effects translate into additional clinical benefits.
My History With Weight Loss, GLP-1s and Peptides.
Get 10% off all of your research materials with code - GLAMFIT
Even though this isn't a personal Mazdutide review, I think my own weight-loss story explains why I'm researching it so deeply.
I've only been significantly overweight for around 10 years.
Before that, I spent most of my life thin and fit.
Health problems and medications changed things for me, and eventually I reached 287 pounds at 5'7".
Seeing myself approaching 300 pounds was a major wake-up call.
I was 38 years old and knew I didn't want to keep heading in that direction.
Around six months ago, I began my current journey using a GLP-1 and researching peptides alongside it.
Today I'm around 217 pounds.
That's approximately 70 pounds gone.
And trust me, I don't miss them. We are not arranging a reunion.
My Next Goal: 200 Pounds!
My immediate goal is 200 pounds.
That means I have only 17 pounds left until I see that number on the scale.
After that, I would ultimately like to lose another 45–55 pounds from where I am now, depending on how I feel, my body composition and what makes sense for me.
This experience is exactly why I'm so interested in emerging medications like Mazdutide.
I'm not researching it because I've decided that I'm switching tomorrow.
I'm researching it because knowledge gives me options.
If there ever comes a point where my current GLP-1 treatment is no longer the best option for me, I'd rather already know what's being studied than start from scratch.
Mazdutide is now firmly on my list of medications I'm watching.
Mazdutide Dosing Schedule.
Get 10% off all of your research materials with code - GLAMFIT
This section needs an important disclaimer because I've seen a lot of incorrect Mazdutide dosing charts floating around online.
Mazdutide does not use the standard 0.25 → 0.5 → 1 → 2 → 2.4 mg Semaglutide schedule.
Those numbers should not be copied over and labeled as Mazdutide dosing.
The Mazdutide clinical-development program has evaluated several different target doses and escalation strategies.
For example, in the higher-dose Phase 2 obesity study, participants assigned to the 9 mg regimen started at 3 mg once weekly and increased by 3 mg every four weeks until reaching 9 mg.
That means the research progression was:
Weeks 1–4: 3 mg weekly.
Weeks 5–8: 6 mg weekly.
Week 9 onward: 9 mg weekly.
That is a description of the clinical-trial protocol, not a DIY dosing recommendation.
GLORY-1 separately evaluated 4 mg and 6 mg target doses, while GLORY-2 investigated the higher 9 mg regimen.
Why titrate at all?
The basic idea is familiar to anyone who has researched GLP-1 medications.
Your digestive system generally doesn't appreciate being introduced to maximum GLP-1 activity like it's being thrown into a surprise party.
Gradual escalation can improve tolerability while the body adjusts.
Supplies Needed.
Get 10% off all of your research materials with code - GLAMFIT
When discussing a prescription injectable medication, the supplies someone needs should be based on the approved pharmaceutical presentation, prescribing information and instructions supplied with the medication in the country where it is legally prescribed.
That being said, I've seen research-vial instructions online that tell people to purchase things like:
• Bacteriostatic water.
• Empty syringes.
• Alcohol pads.
• Needles.
• Research peptide vials.
I can be extremely interested in the science without pretending that every product carrying the same chemical name is interchangeable.
Reconstitution Steps.
You'll find websites providing calculations such as:
10 mg + 2 mL bacteriostatic water = 5 mg/mL.
Mathematically, yes, that concentration calculation is straightforward.
But that doesn't establish that a particular vial is sterile, correctly identified, pharmaceutical grade, accurately dosed, stable after mixing or appropriate for human injection. That's why you need to verify every single company you purchase from. Check for up to date, traceable COA's.
I actually think that's important in the peptide community.
Educational information and preparation instructions are two different things.
The Mazdutide clinical trials tell us a great deal about what the investigational pharmaceutical medication can potentially do.
They don't automatically validate the purity, concentration, sterility or stability of an independently purchased research vial. That's why I always recommend researching the company you are using and verify that they do full testing.
My Final Takeaway on Mazdutide.
Get 10% off all of your research materials with code - GLAMFIT
After spending so much time researching Mazdutide, I understand why it's getting attention.
The GLP-1 world is evolving ridiculously fast.
A few years ago, most people couldn't tell you what GLP-1 stood for.
Now we're casually discussing GLP-1/GIP dual agonists, GLP-1/glucagon dual agonists and triple receptor agonists over our morning coffee.
What a time to be alive.
Mazdutide stands out because it takes a different approach from Tirzepatide.
Instead of combining GLP-1 + GIP, Mazdutide combines GLP-1 + glucagon.
That could potentially offer a powerful combination, reduced appetite + improved glucose regulation + increased energy expenditure + changes in fat and liver metabolism.
And the clinical results aren't small.
Phase 3 research has demonstrated meaningful weight loss with 4 mg and 6 mg, while the newer 9 mg GLORY-2 program produced average weight reductions approaching 20% in participants without diabetes after 60 weeks.
Mazdutide has also shown improvements in waist circumference, liver fat and multiple cardiometabolic measurements.
Those are exactly the kinds of results that make me want to keep following this medication.
But I'm equally interested in the limitations.
It's still a relatively new medication. Most of its major clinical program has involved Chinese participants. Long-term worldwide real-world evidence is still developing. Higher doses can produce substantial gastrointestinal side effects. BUT that's the same for all GLPs.
And most importantly for my U.S. readers, Mazdutide is not currently FDA-approved in the United States.
Where Mazdutide Fits Into My Own Weight-Loss Research.
Get 10% off all of your research materials with code - GLAMFIT
Personally, I've gone from 287 pounds to approximately 217 pounds during the last six months of my weight-loss journey.
That's 70 pounds down.
My next stop is 200 pounds.
Seventeen more pounds.
I can practically see it from here.
After that, I still have a bigger long-term goal ahead of me. I'd ultimately like to lose another 45–55 pounds from where I am now.
But I'm taking this journey one milestone at a time.
Researching medications like Mazdutide isn't about chasing every new compound that appears online.
For me, it's about understanding what's coming next.
If my needs change in the future, or if I ever need to discuss switching GLP-1-based treatments with a medical professional, I want to know what my options are and what actual clinical evidence supports them.
And based on everything I've researched so far, Mazdutide is absolutely one of the next-generation weight-loss medications I'll be watching closely.
It combines a familiar GLP-1 mechanism with something different: glucagon receptor activation.
The result could be a treatment that doesn't only address appetite, but also targets several other pieces of metabolic health.
Will Mazdutide eventually become a major obesity medication in the United States?
We'll have to wait and see.
But considering how quickly obesity medicine has changed during the last few years, I wouldn't count it out.
My weight-loss journey still has a ways to go, and apparently my research journey does too.
At this point I may reach my goal weight before I reach the bottom of the GLP-1 rabbit hole.
And honestly?
I'm starting to think that rabbit hole doesn't have a bottom.
Frequently Asked Questions About Mazdutide.
Get 10% off all of your research materials with code - GLAMFIT
1. What is Mazdutide?
Mazdutide, also known as IBI362 or LY3305677, is a once-weekly injectable medication that activates both GLP-1 and glucagon receptors. It was developed to support weight loss, blood-sugar control, and overall metabolic health.
2. Is Mazdutide FDA-approved in the United States?
No. As of 2026, Mazdutide is not FDA-approved in the United States. It has received approval in China for weight management and type 2 diabetes, while development and research continue in other regions.
3. How much weight can you lose with Mazdutide?
Clinical trials have reported substantial weight loss, with some higher-dose studies showing average reductions approaching 18% to 20% of starting body weight over longer treatment periods. Individual results can vary quite a bit.
4. How does Mazdutide work for weight loss?
Mazdutide works through two different pathways. Its GLP-1 activity can help reduce appetite, slow digestion, and improve blood-sugar control, while glucagon receptor activation may increase energy expenditure and support fat metabolism.
5. How is Mazdutide different from Tirzepatide?
The biggest difference is the second receptor they target. Mazdutide activates GLP-1 and glucagon receptors, while Tirzepatide activates GLP-1 and GIP receptors. That means Mazdutide may have a stronger focus on energy expenditure and liver-fat metabolism.
6. Is Mazdutide the same as Retatrutide?
No. Mazdutide is a dual agonist targeting GLP-1 and glucagon. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
7. What are the most common Mazdutide side effects?
The most commonly reported side effects are gastrointestinal and can include nausea, vomiting, diarrhea, reduced appetite, and other digestive changes. These effects can vary depending on the dose and the individual.
8. How often is Mazdutide taken?
Mazdutide has been studied as a once-weekly injection. Clinical trials have used gradual dose increases to help improve tolerability.
9. Does Mazdutide help with more than weight loss?
Potentially, yes. Research has shown improvements in areas such as blood sugar, waist circumference, blood pressure, cholesterol, triglycerides, liver fat, and other metabolic markers.
10. Is Mazdutide better than Semaglutide or Tirzepatide?
There really isn't one medication that is automatically "best" for everyone. Mazdutide has shown very promising results, but Semaglutide and Tirzepatide already have much more real-world use in the United States. The best option depends on effectiveness, side effects, medical history, availability, and what a healthcare provider recommends.
11. Can Mazdutide reduce liver fat?
Clinical research suggests that Mazdutide may significantly reduce liver fat and improve certain liver-related metabolic markers, which is one of the reasons I find this medication so interesting to research.
12. Why am I researching Mazdutide during my own weight-loss journey?
I've been on my own weight-loss journey for around six months and have lost about 70 pounds so far, going from 287 pounds to around 217 pounds. I'm researching Mazdutide because I like knowing what options may be available in the future if my current GLP-1 treatment ever stops being the right fit for me. I still have more weight I want to lose, so learning about newer medications like Mazdutide helps me stay informed instead of scrambling for answers later.
Get 10% off all of your research materials with code - GLAMFIT
~ Written by Rachael Tam.
~ Photos by Rachael Tam.
~ Topic - Glps and Weight-Loss.
~ For PR Offers, email me at - bfh.artistry@gmail.com.
~ My Linktree link - https://linktr.ee/rachaeltam.
~ Check out my ShopMy Store.
~ Shop my Amazon Storefront.
~ Check out my Walmart Storefront.
~ Shop my Ulta Beauty Storefront.
~ Check out my Target Storefront.
~ Shop my Kitsch Store.
~ Check out my Sephora Storefront.
~ Join my Peptide & Biohacking discord group.
Comments
Post a Comment